Send to

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2013 Aug 1;2(8):e25913. Epub 2013 Jul 31.

Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.

Author information

  • 1Department of Oncology; Ludwig Cancer Research Center; University of Lausanne; Lausanne, Switzerland.


B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. We have recently demonstrated that the expression of B7-H4 on the surface of malignant cells in vivo is inducible, and that novel anti-B7-H4 recombinant antibodies can reverse the inhibition of tumor-specific T cells. Thus, antibodies targeting the B7-H4 pathways may extend the survival of cancer patients by restoring T cell-mediated antitumor responses.


B7-H4; cell surface expression; immunotherapy; ovarian cancer; recombinant antibodies; targeting

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Write to the Help Desk